The efficacy of oral montelukast versus intranasal fluticasone furoate in reducing the severity of pediatric sleep-disordered breathing: A randomized clinical trial.
Sarah Rothman, Ronly Har-Even, Ofer Israel et al.
✦ AI-curated · Sources linked
In 30 seconds
This randomized clinical trial evaluated the efficacy of oral montelukast versus intranasal fluticasone furoate in reducing sleep-disordered breathing (SDB) severity in children aged 2-15 with adenotonsillar hypertrophy. Both treatments improved median Pediatric Sleep Questionnaire scores, with montelukast showing a significant reduction in tonsillar size (p = 0.008) compared to fluticasone furoate.
Key findings
- Montelukast reduced the median PSQ score from 0.45 to 0.28 (p = 0.003).
- Fluticasone furoate reduced the median PSQ score from 0.43 to 0.36 (p = 0.006).
- Moderate-to-severe sleep apnea prevalence decreased from 67% to 41% with montelukast (p = 0.035).
- Only montelukast significantly reduced tonsillar size (p = 0.008).
Why it matters
Understanding the comparative efficacy of montelukast and fluticasone furoate in managing pediatric SDB can guide clinicians in selecting appropriate non-surgical treatment options, potentially reducing the need for surgical interventions in children with adenotonsillar hypertrophy.